Overview

Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2022-07-22

Target enrollment:

Participant gender:

Summary

This pilot phase I clinical trial studies how well copper 64Cu-DOTA-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back. Diagnostic procedures, such as copper 64Cu-DOTA-daratumumab positron emission tomography, may help evaluate the extent of multiple myeloma in patients prior to the initiation of treatment and ultimately monitor disease status/response during and post treatment.

Phase:

Phase 1

Details

Lead Sponsor:

City of Hope Medical Center

Treatments:

Antibodies, Monoclonal
Copper
Daratumumab